$TELA News
Last published 1d ago
- 1d agoTELATELA Bio, Inc. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoTELATELA Bio Reports Third Quarter 2026 Financial ResultsGlobeNewswireReduced sequential operating loss by 21%, including cost of realignment
- 5d agoTELATELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (
- 5d agoTELATELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 2w agoTELATELA Bio to Announce Third Quarter 2026 Financial ResultsGlobeNewswireMALVERN, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 2mo agoTELATELA Bio Announces COO / CFO Transition and Strategic Cost Reduction InitiativeGlobeNewswireMALVERN, Pa., Aug. 31, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction
- 3mo agoTELATELA Bio Reports Second Quarter 2026 Financial ResultsGlobeNewswireMALVERN, Pa., Aug. 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported
- 3mo agoTELATELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 3mo agoTELABFLYTELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and DirectorGlobeNewswireMALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction
- 3mo agoTELATELA Bio to Participate in the Canaccord Genuity 46th Annual Growth ConferenceGlobeNewswireMALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 3mo agoTELATELA Bio to Announce Second Quarter 2026 Financial ResultsGlobeNewswireMALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 5mo agoCNXUESTAINMDPCRX+1After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast InsteadGlobeNewswireConexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine institutes in the world. For investors watching how breast reconstruction — and the wider field of tissue
- 6mo agoTELATELA Bio Reports First Quarter 2026 Financial ResultsGlobeNewswireMALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial
- 6mo agoTELATELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 6mo agoACRXANIKAXGNBEAT+6TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesGlobeNewswireMALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a
- 6mo agoTELATELA Bio to Announce First Quarter 2026 Financial ResultsGlobeNewswireMALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 7mo agoTELATELA Bio Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireMALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported
- 8mo agoTELATELA Bio to Announce Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireMALVERN, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 8mo agoTELATELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., Feb. 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 9mo agoTELATELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 11mo agoTELATELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 11mo agoTELATELA Bio to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireMALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the
- 11mo agoTELATELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 12mo agoTELATELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireMALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the
- 12mo agoTELATELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit FacilityGlobeNewswireMALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported
- 1y agoTELATELA Bio to Announce Third Quarter 2025 Financial ResultsGlobeNewswireMALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 1y agoTELATELA Bio Appoints William Plovanic to Board of DirectorsGlobeNewswireMALVERN, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MALVERN, Pa., November 3, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative
- 1y agoTELATELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa ColleranGlobeNewswireMALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today
- 1y agoTELATELA Bio, Inc. (TELA) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoTELATELA Bio Reports Second Quarter 2025 Financial ResultsGlobeNewswireMALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported
- 1y agoTELATELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 1y agoTELATELA Bio to Participate in the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewswireMALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the
- 1y agoTELATELA Bio to Announce Second Quarter 2025 Financial ResultsGlobeNewswireMALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 1y agoTELATELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that
- 1y agoTELATELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia RepairGlobeNewswireMALVERN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the
- 1y agoTELATELA Bio Appoints Jeffrey Blizard as PresidentGlobeNewswireMALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the
- 1y agoTELATELA Bio to Participate in the 2025 Jefferies Global Healthcare ConferenceGlobeNewswireMALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the
- 1y agoTELATELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 1y agoTELATELA Bio Reports First Quarter 2025 Financial ResultsGlobeNewswireMALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported
- 1y agoTELATELA Bio to Announce First Quarter 2025 Financial ResultsGlobeNewswireMALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 1y agoTELATELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive SurgeryGlobeNewswireMALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of
- 1y agoTELATELA Bio Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireMALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported
- 1y agoTELATELA Bio to Announce Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireMALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 1y agoTELATELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 1y agoTELATELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., Jan. 24, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 1y agoTELATELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,
- 1y agoTELATELA Bio to Participate in Piper Sandler's 36th Annual Healthcare ConferenceGlobeNewswireMALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the
- 2y agoTELATELA Bio, Inc. (TELA) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoTELATELA Bio Reports Third Quarter 2024 Financial ResultsGlobeNewswireMALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported
- 2y agoTELATELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,